Cases
Ohr Pharmaceutical, Inc. (NASDAQ: OHRP)
Securities Class Action
Overview
Overview
- Date:
- 4/2/2018
- Company Name:
- Ohr Pharmaceutical, Inc.
- Stock Symbol:
- OHRP
- Class Period:
- FROM 6/24/2014 TO 1/4/2018
- Status:
- Closed/Complete
- Court:
- U.S. District Court: Southern District of New York
NEW YORK, April 2, 2018 – Bragar Eagel & Squire, P.C. announces to investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) securities between June 24, 2014 and January 4, 2018 (the “Class Period”). Investors have until April 16, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that (1) Ohr’s lead product Squalamine would not produce vision improvements and was commercially not viable; and (2) as a result of the foregoing, Defendants’ statements about Ohr’s business, operations, and prospects were misleading and/or lacked a reasonable basis.
On January 5, 2018, Ohr announced topline data from its MAKO study to evaluate the use of Squalamine combination therapy for the treatment of wet-AMD. Ohr announced the MAKO study did not meet its primary efficacy endpoint. Following this news, shares of Ohr fell from a close of $2.02 on January 4, 2018, to a close of $0.38 on January 5, 2018.
If you purchased or otherwise acquired Ohr securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that (1) Ohr’s lead product Squalamine would not produce vision improvements and was commercially not viable; and (2) as a result of the foregoing, Defendants’ statements about Ohr’s business, operations, and prospects were misleading and/or lacked a reasonable basis.
On January 5, 2018, Ohr announced topline data from its MAKO study to evaluate the use of Squalamine combination therapy for the treatment of wet-AMD. Ohr announced the MAKO study did not meet its primary efficacy endpoint. Following this news, shares of Ohr fell from a close of $2.02 on January 4, 2018, to a close of $0.38 on January 5, 2018.
If you purchased or otherwise acquired Ohr securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.